Ce bulletin signale des articles du web anglophone portant sur les divers champs d'intervention de l'Institut national du cancer. La publication se fait sur un rythme quotidien.
In mice, the experimental drug, called BAI1, prevented doxorubicin-induced heart damageExit Disclaimer, and did so without interfering with doxorubicin’s ability to kill cancer cells, researchers reported in Nature Cancer.
Researchers have enhanced a new method for inhibiting the protein HSP72, known to be important in helping cancer cells survive and resist treatment, which will help scientists move closer to discovering a new cancer drug that targets the protein.
The discovery comes from their research into the role of an amino acid in tumor development and a potential method for reversing the process. Their study appears in Nature Cancer.
Supplemental Biologics License Application (sBLA) Accepted for KEYTRUDA Monotherapy in Patients Whose Tumors Are Tumor Mutational Burden-High (TMB-H) Who Have Progressed Following Prior Treatment.
The Phase III ASCENT study was designed to evaluate how its antibody-drug conjugate dubbed sacituzumab govitecan impacts progression-free survival, overall survival and response rates compared to chemotherapy.
Leading cancer experts have recommended a one-week course of radiotherapy and delaying surgery as the best way to treat patients with bowel cancer during the covid-19 pandemic.
Approval Based on Positive Results from the Phase 3 ALTA-1L Trial Showing ALUNBRIG Demonstrated Superior Overall and Intracranial Effectiveness over Crizotinib in the First-line Setting.
CRUK, which funds around half of all oncology research in the U.K., said it will be axing funding to its “existing grants and institutes by up to 10% and its national network of Centres by around 20%.”
The Cancer Research UK scientific family has provided much-needed kit and machinery, and volunteered their skills, to the national testing labs being set up across the devolved nations – an important effort to scale up the UK’s testing capacity. At local levels, our scientists are converting their cancer labs to testing hubs.
According to Antonio Passaro, from the European Institute of Oncology (IEO) in Milan, Italy, protecting medical oncologists from contracting the virus is key to ensuring that continuity of care is maintained and that cancer patients can safely attend visits and receive treatment in due time.